A carregar...
Adalimumab in Psoriasis: How Much is Enough?
Biologic therapies targeting tumor necrosis factor have revolutionized treatment of immune-mediated inflammatory diseases such as psoriasis, but optimal dosing and appropriate use of therapeutic drug monitoring are not yet fully understood. Wilkinson et al. explore these questions in a real-world ps...
Na minha lista:
| Publicado no: | J Invest Dermatol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7357200/ https://ncbi.nlm.nih.gov/pubmed/30579425 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jid.2018.08.012 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|